Table 5.
Attainment of PK–PD target values by various dosing regimens
| PK–PD target values | PK–PD study | Simulation | |
|---|---|---|---|
| 50 mg twice daily | 100 mg twice daily | 100 mg once daily | |
| 61 patients, 76 strains | 13 patients, 15 strains | n = 6,734 (74 × 91) | |
| fAUC0–24h/MIC ≥ 30 | 90.8 % | 93.3 % | 90.6 % |
| fC max/MIC ≥ 2 | 89.5 % | 93.3 % | 92.4 % |
| Clinical efficacy ratea | 92.3 % (96/104) | 93.1 % (27/29) | Not tested |
aThe clinical efficacy analysis set (n = 133) included patients in whom the causative pathogen could not be identified [15]